Floatz logo

281 assets in Gastric Cancer

Therapeutic assets addressing Gastric Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Rivoceranib
Gastric Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P4BBB (73)
Fluorouracilum
Gastric Cancer
I-Mab Biopharma US LimitedP4BB (69)
Oxaliplatin
Gastric Cancer
Qilu Pharmaceutical Co., Ltd.P3BB (66)
Capecitabine
Gastric Cancer
I-Mab Biopharma US LimitedP3BB (64)
Cis-Diamminedichloroplatinum Ii
Gastric Cancer
Qilu Pharmaceutical Co., Ltd.P3BB (64)
Docetaxel
Gastric Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P3BB (64)
Epirubicin
Gastric Cancer
Rondo TherapeuticsP3BB (64)
Irinotecan
Gastric Cancer
Shenzhen Xinhe BiomedicalP4BB (64)
Pembrolizumab
Gastric Cancer
Eikon TherapeuticsP3BB (64)
Cyclophosphamide
Gastric Cancer
Vall d'Hebron Institute of OncologyP3B (63)
Muamycin
Gastric Cancer
City of Hope Medical CenterP2B (63)
Tucatinib
Gastric Cancer
Seagen, a wholly owned subsidiary of PfizerP2B (60)
Carboplatin
Gastric Cancer
Qilu Pharmaceutical Co., Ltd.P2B (59)
Nivestim
Gastric Cancer
Mayo ClinicP2B (59)
Pyrotinib
Gastric Cancer
BeOne MedicinesP2B (59)
Talazoparib
Gastric Cancer
National Cancer Institute (NCI)P2B (59)
Zanidatamab
Gastric Cancer
Jazz PharmaceuticalsP2B (59)
Ciprofol
Gastric Cancer
RenJi HospitalP4B (58)
Fludarabine
Gastric Cancer
Vall d'Hebron Institute of OncologyP2B (58)
Nivolumab
Gastric Cancer
I-Mab Biopharma US LimitedP2B (58)
Propofol
Gastric Cancer
RenJi HospitalP4B (58)
Tislelizumab
Gastric Cancer
BeOne MedicinesP2B (58)
Cetuximab
Gastric Cancer
BeOne MedicinesP2B (57)
Fulvestrant
Gastric Cancer
BeiGeneP2B (57)
GEH300079 (68Ga)
Gastric Cancer
GE HealthcareP2/3B (57)
Sargramostim
Gastric Cancer
Mayo ClinicP2B (57)
Trastuzumab
Gastric Cancer
Enliven TherapeuticsP2B (57)
Atezolizumab
Gastric Cancer
Genentech, Inc.P2B (56)
Durvalumab
Gastric Cancer
Second Affiliated Hospital of Guangzhou Medical UniversityP2B (56)
TIL
Gastric Cancer
Intima Bioscience, Inc.P2CCC (55)
Ipilimumab
Gastric Cancer
Neonc Technologies, Inc.P2CCC (54)
Trastuzumab Deruxtecan
Gastric Cancer
National Cancer Institute (NCI)P1/2CCC (54)
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre
Gastric Cancer
Thomas Jefferson UniversityP2CCC (53)
Disitamab Vedotin
Gastric Cancer
Seagen, a wholly owned subsidiary of PfizerP2CCC (53)
Human Adenovirus C Serotype 5
Gastric Cancer
Thomas Jefferson UniversityP2CCC (53)
Riluzole
Gastric Cancer
University of California, IrvineP2CCC (53)
Teonanacatl
Gastric Cancer
Psyence Australia Pty LtdP2CCC (53)
Datopotamab Deruxtecan
Gastric Cancer
AstraZenecaP2CCC (52)
Fludeoxyglucose
Gastric Cancer
National Cancer Institute (NCI)P2CCC (52)
Givastomig
Gastric Cancer
I-Mab Biopharma US LimitedP2CCC (52)
Levofolinic Acid
Gastric Cancer
Shenzhen Xinhe BiomedicalP2CCC (52)
Olaparib
Gastric Cancer
Qilu Pharmaceutical Co., Ltd.P2CCC (52)
Pemigatinib
Gastric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2CCC (52)
Rilvegostomig
Gastric Cancer
AstraZenecaP2CCC (52)
S-1
Gastric Cancer
Genentech, Inc.P2CCC (52)
Surufatinib
Gastric Cancer
RenJi HospitalP2CCC (52)
FAPI74
Gastric Cancer
National Cancer Institute (NCI)P2CCC (51)
Lenvatinib
Gastric Cancer
Peking UniversityP2CCC (51)
Terelizumab
Gastric Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityP2CCC (51)
Avelumab
Gastric Cancer
Ocellaris Pharma, Inc.P2CCC (48)
Showing 1 to 50 of 281 assets
PreviousPage 1 of 6Next